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A relatively noncytopathic virus, lymphocytic choriomeningitis virus (LCMV), 1
prevents the development of insulin-dependent diabetes mellitus (IDDM) in non-
obese insulin-dependent diabetes (NOD) mice (1, 2). Typically, >90% ofNOD fe-
male mice, by 9 mo of age, develop hyperglycemia, hypoinsulinemia, and lympho-
cytic infiltrates in the islets of Langerhans, with a cell destruction . However, their
age- and sex-matched counterparts persistently infected since birth withLCMV are
quite normal with respect to concentrations of blood sugar and pancreatic insulin .
LCMV is a negative-strand RNA virus with an ambisense coding strategy (3,
4) . The viral genome is segmented into two strands, a large (L) and a small (S)RNA
of 7.2 and 3.4 kb, respectively. The open reading frame (ORF) at the 3' end of the
L RNA segment encodes a large (L) protein (molecular mass of-200 kD) that is
the virus transcriptase/replicase . The 5' ORF encodes a protein called Z (molecular
mass of 10-12 kD) that contains a cysteine2-histidine2 zinc finger motif (4) . The
ORF for the L gene at the 3' end is complementary to the viral genome (negative
sense), and the ORF of Z gene at the 5' end is of genomic sense (positive sense)
(4) . The S segment encodes three major structural proteins : from the 3' end, the
internal nucleocapsid protein (NP ; molecular mass, 63 kD) and from the 5' end,
two surface glycoproteins (GPs)GP-1 (molecular mass, 43 kD) andGP-2 (molecular
mass, 36 kD) that are derived from a common precursor polypeptide, GP-C (5, 6) .
The NP gene at the 3' ORF encoding the NP iscomplementary to the viral genome
(negative sense), whereas the GP-C ORF at the 5' end is of positive sense (6-8) .
We utilized this knowledge ofthe genomic structure ofLCMV to determine whether
the entire genome or, in contrast, a component part was needed for successful viral
therapy to prevent IDDM . Towards that end, we first determined the differing abili-
ties ofindividualLCMV strains to prevent the IDDM inNOD mice . We then used
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these data to select viral reassortants for use in mapping the viral genes that inhibit
the diabetes of NOD mice.
Materials and Methods
Mice, ClinicalMeasurements, andInitiation ofVirus Persistence.
￿
NOD mice breederswere orig-
inally obtained from K. Lafferty, University of Colorado Medical School, Denver, CO. The
NOD colony was established at Scripps Clinic from brother-sister matings of these breeders
and was observed twice weekly for general health and length of survival. The incidence of
IDDM, as defined by blood glucose of >300 mg/dl, was 90% or greater in all the mice by
9 mo ofage or older. Blood glucose concentrations of individual mice were determined every
2 or 3 mo afterbirth (1, 2). For glucose tolerance testing, each animal's blood was sampled
immediately before administering 2 mg of glucose/kg ofbody weight, intraperitoneally. Blood
samples were taken again 1 h later and tested for sugar concentrations; those that remained
two and a half times the preglucose challenge levels were considered abnormal (9). Insulin
was extracted from each pancreas and its concentration measured by RIA with rat insulin
as a standard and A-14'251-labeled bovine insulin as a tracer (2). To establish persistent in-
fection, randomly selected mice were inoculated intracerebrally within the first 18 h of life
with 103 plaque-forming units (PFU) of either reassortants or the parental strains of LCMV.
Details of the inoculation procedure, as well as the plaque assay, to measure LCMV persis-
tent infection have been reported (2, 10). Deposition of viralnucleic acid sequences was studied
in persistently infected mice by using sections ofwhole animals and LCMV 32P nucleic acid
hybridization (11).
Viruses and Generation of Reassortants.
￿
The passage histories of LCMV strains Armstrong
CA1371 53B (ARM), Pasteur, Traub, and WE, and the Clone 13 variant of ARM CA1371
53b, appear elsewhere (12-14). Individual LCMV strains were cloned and plaque purified
three times on Vero cells. Thereafter, a stock was prepared through one passage in BHK-21
cells. Reassortants between Clone 13 and LCMV strain Pasteur CIPV 76001 (12) were gener-
ated, plaque purified, characterized by hybridization, and prepared as viralstocks (14). Stocks
of the two parental genotypes (L RNA/S RNA, Clone 13/Clone 13, Pasteur/Pasteur) and
reassortant genotypes (clone 13/Pasteur, Pasteur/Clone 13) had titers ranging from 101 to
6 x 101 PFU/ml.
Sequence Analysis.
￿
Viral RNA was isolated from the Pasteur and ARM Clone 13 strains
and from the Pasteur/ARM Clone 13 and ARM Clone 13/Pasteur reassortants for sequence
analysis. Direct RNA sequence analysis using radioactive oligonucleotide primers and dideoxy
chain termination has been described (4, 15). Oligonucleotides that anneal to both ARM
and Pasteur viral RNA were chosen to identify the L and S RNAs of the reassortants. The
oligonucleotide, CTGTTGATATCTTCAATCTG, chosen to identify the L RNA anneals to
the 5' end (bases 310-329) (4). The oligonucleotide chosen to identify the S RNA, CAT
GAGTGTGTGGTCAAAGGTC, anneals to the 5' end (bases 473-494) (16). Reactions were
performed simultaneously with RNA from parental strains and reassortants and compared
in parallel on buffer-gradient thin gels (17).
In Situ Hybridization and Infective Center Analysis.
￿
In situ hybridization studies of lympho-
cytes harvested from NOD mice using a 35S cDNA probe to the LCMV GP are described
in the accompanying paper (2). Concurrently, infectiouscenter analysis was done on materials
from the same individual mice (10). Briefly, 2 x 106 , 5 x 105, 2 x 105, or 2 x 104 lympho-
cytes were plated on confluent layers ofVero cells grown on petri dishes (Falcon Laboratories,
Oxnard, CA) after absorption for 60 min at 37°C; 0.5% agarose was added, plates were
incubated for 6-7 days at 37°C, and overlayed with crystal violet. The results were calculated
as the number of infectious centers per 106 viable PBL plated.
Histopathology.
￿
Pancreatic tissue was fixed in formalin, sectioned, and stained with hema-
toxylin and eosin. The percentage of normal islets of Langerhans present in each pancreas
was calculated by counting at least 15 islets per pancreas and determining the number not
destroyed by infiltrating lymphoid cells.OLDSTONE ET AL.
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Results
Prevention ofIDDMin NODMice by Distinct Strains ofLCMV .
￿
Inoculation ofgroups
of 15 or more newborn NOD mice, each with one of the four strains of LCMV,
i.e., ARM, Pasteur, Traub, and WE, and avariant ofLCMVARM, Clone 13; resulted
in persistent infection. The evidencewasvirusrecovered from the blood and tissues
andviral nucleic acid sequences visible in multiple tissues of animals killed and ex-
amined at increasing intervals of age. During the course of infection, the amount
ofvirus carried and distribution of deposited LCMV sequences were apparently
similar, regardless ofthe viral strain used to initiate infection. For example, testing
ofat least six individual sera from 4-mo-old mice inoculated with Clone 13, ARM,
Pasteur, Traub, or WE showed titers that ranged from 4 x 104 to 5 x 106 PFU/ml.
By whole mouse body sections, viral sequences in 4-6-mo-old persistently infected
mice were routinelynotedin brains, salivary glands, thymuses, lungs, livers, spleens,
adrenals, and kidneys.
Infection with ARM, Pasteur, Traub, or WE was followed by near normal sur-
vival rates and the prevention ofIDDM. Micepersistentlyinfected with such viruses
had survival rates that exceed 9017o over the 12 mo of observation. Further, these
mice had normal blood glucose and pancreatic insulinlevels as well as normal mor-
phology of the islets ofLangerhans (Table I). In contrast, as also shown in Table
1, uninfected NOD mice or those persistently infected with Clone 13 developed the
elevated blood sugar and other manifestation of IDDM typical for this strain. At
9 mo of age, the incidence ofIDDM in uninfected NOD mice was 90%, and, in
Clone 13, persistently infected mice 76%. In contrast, NOD mice matched by age
and gender, but persistently infected with LCMV ARM, Pasteur, Traub, or WE,
had a <5 17o incidence of IDDM when 9 mo old.
TABLE I
Occurrence of IDDM in Female NOD Mice Persistently Infected with Several Strains of LCMV
Mice were given 103 PFU ofLCMV within the first 18 h of birth. LCMV strains used were Pasteur, Traub,
WE, Armstrong 1371, Clone 53b, or its variant ARM Clone (Cl) 13. Such mice carried infectious virus
throughout theirlives. Blood glucose concentrations were determined by the glucose oxidase method. The
percent ofnormal islets of Langerhans was calculated by counting up to 15 islets per pancreas and deter-
mining the number not destroyed by infiltrating lymphoid cells.
" p < 0.01 compared with NOD mice infected at birth with LCMV Pasteur, Traub, WE, or ARM.
Group of
NOD female
No. of
mice
3 mo
Blood glucose
mg/dl
Manifestation
6 mo
Blood glucose
mg/dl
of IDDM at:
9
Blood glucose
mg/dl
mo
Normal islets
Uninfected 40 172 t 6 291 t 35* 412 t 32* <5
LCMV infected
Pasteur 17 129 1 4 185 1 9 134 1 4 >70
Traub 18 151 1 5 126 1 5 126 1 5 ND
WE 54 16 132 1 3 137 1 3 116 1 8 ND
ARM 19 154 1 4 126 1 6 155 1 11 >70
ARM Clone 13 18 194 t 9 247 t 25* 316 t 31* <102094
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Reassortants between LCMV ARM Clone 13 and LCMV Pasteur Map the Prevention of
IDDM to the S RNA of Pasteur. Reassortant between LCMV Pasteur, which pre-
vents IDDM, and LCMVARMClone 13, whichdoes not, were made from reported
stocks (14), retested biochemically, and inoculated into newborn NOD mice. The
identity of each reassortant was confirmed by using oligonucleotides that annealed
tobothPasteur andClone 13 LorS RNA. TheresultsinFig. 1 show thatPasteur/ARM
Clone 13 contained the characteristic Pasteur L RNA and ARM Clone 13 S RNA
sequences, while that ofARM Clone 13/Pasteurreassortant hadARM L andPasteur
S RNA sequences. Thestrain-specific sequences(Fig. 1) reveal 84% nucleotide identity
and 92% aminoacididentity intheregion oftheL RNA analyzed, and 84% nucleotide
identity and 88% amino acid identity in the region of the S RNA analyzed.
The use ofthese reassortant showed that the L RNA Pasteur/S RNA Pasteur (pa-
rental Pasteurstrain)and theL RNAofClone 13/S RNA Pasteur(therapeutic reas-
sortant) were associatedwith normal concentrations ofblood sugar. In contrast, the
L RNA Clone 13/S RNA Clone 13 (parental Clone 13) and the L RNA Pasteur/S
RNAClone 13 (nontherapeutic reassortant) lefthyperglycemiaunchecked, as Table
If shows. Inconfirmation ofthese findings, lymphocytes infiltrated the isletsofLanger-
hans in mice receiving the Clone 13 parent or the reassortant without Pasteur S
RNA (Table II, Fig. 2). Yet, >75% ofthe islets were normal in NOD mice persis-
tently infected withthe parental Pasteurstrain orthe reassortant containingPasteur
S RNA and Clone 13 L RNA (Table II, Fig. 2).
The amountsofvirusin seraofNOD micepersistently infected withClone 13/Clone
13, Pasteur/Pasteur, Pasteur/Clone 13, and Clone 13/Pasteurwere equivalent. Thus,
in 3-mo-old animals, the titers f 1 SE were 2.9 x 105 t 0.7 for 10 mice injected
with Pasteur/Pasteur; 2.1 x 105 ± 0.7 for nine mice given Clone 13/Clone 13; 1.7 x
105 t 0.3 for 10 mice receiving Pasteur/Clone 13, and 2 .5 x 105 ± 0.5 for 11
recipients of Clone 13/Pasteur.
Sequence Differences between LCMV Pasteur and ARM Clone 13 in GP and NP .
￿
The
S RNA ofLCMV encodes but two viral proteins, GP and NP (3, 5, 6). Since the
S RNA of LCMV Pasteur aborted IDDM of NOD mice, but the corresponding
S RNA ofARM Clone 13 did not (Table II), we compared the areas ofhomology
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FIGURE 1 .
￿
Selected amino acids and nucleotide sequence comparisons between ARM Clone
13 andPasteur LCMV virusesused to form reassortants. Aminoacidsthat differ betweenARM
Clone 13 and Pasteur are circled and nucleotides that differ are underlined. The single letter
code foramino acids appear above each codon of viral RNAsequences. A, alanine; C, cysteine;
D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K,
lysine;L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine;
T, threonine; V, valine; W, tryptophan; Y, tyrosine.OLDSTONE ET AL.
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TABLE II
Prevention ofIDDM Maps to the S RNA of LCMV Pasteur
Manifestations of IDDM' at:
3 mo
￿
5 Mo
￿
7 mo
￿
9 Mo
103 PFU of parental and reassortment viruses were inoculated into newborn NOD mice <18 h old.
' Blood glucose was determined by the glucose oxidase method. The percent of normal islets of Langerhans
was calculated by counting up to 15 islets per pancreas and determining the number not destroyed by infiltrat-
ing lymphoid cells.
s p < 0.005.
anddivergence inboth proteins encoded bythese two viralstrains. The GPofLCMV
has 499 amino acids, ofwhich, 474 arein similarpositions in Clone 13 and Pasteur,
whereas 25 amino acids are replaced, indicating adivergence of5%. The disparate
amino acids and their positions are noted in Fig. 3. For the NP, divergence is 3.9%
(Fig. 3), with 22 amino acids replaced of the 558 total.
Replication ofLCMV Pasteur and LCMVARM Clone 13 in CD4' Lymphocytes.
￿
The
last series ofexperiments documented the replication ofvirus in lymphocytes and
assessed thelymphocyte subset infected. Adult NOD mice persistently infected with
either Pasteur or ARM Clone 13 since birth contained LCMV predominantly in
their CD4' lymphocytes. Fig. 4 records the presence of infective centers in CD4'
lymphocytes obtained from 7-mo-old NOD mice persistently infected with LCMV
Pasteur. By FAGS analysis, <1.7% of CD4°f lymphocytes were contaminated with
CD4' cells (Fig. 4). A similar tropism for these CD4' cells was noted after infec-
tious centers assay ofmice infected with ARM Clone 13. Approximately twice as
many CD4' cells from Pasteur-infected mice scored as infectious centers as from
mice infected with ARM Clone 13.
Discussion
In this paper, we show that the S RNA segment of LCMV Pasteur is linked to
the prevention of IDDM associated with NOD mice. This conclusion was deter-
mined byfirstshowingthat the LCMVARM variant, Clone 13, failed toabortIDDM,
whereas other LCMV strains, including LCMV Pasteur, prevented the disease.
Second, using reassortants between ARM Clone 13 and Pasteur to produce persis-
tentinfection in NOD mice, we found that the S RNAofPasteurpreventedIDDM,
but the L RNA of this virus did not.
Complete nucleotide sequencing of the S RNA ofPasteur and Clone 13 (16; Sal-
vato, M. S., K. J. Schweighofer, E. M. Shimomaye, and M. B. A. Oldstone, manu-
script submitted forpublication) showed a5%divergence in the GPmoleculesfrom
both viruses. The causewas 25 different aminoacidsofthe 499 that composePasteur
Reassortants
S RNA/L RNA
Blood
glucose
mg/dl
Blood
glucose
mg/dl
Blood
glucose
mg/dl
Blood
glucose
mg/dl
Pancreatic
insulin
mg/gm
Normal
islets (%)
Pasteur/Pasteur 156 t 4 153 t 8 164 t 8 162 t 6 55 t 9 >80
Cl 13/Cl 13 188 t 8 258 t 12 312 t 42: 369 t 49: 17 t 5$ <20
Cl 13/Pasteur 161 t 5 284 t 51 317 t 501 335 471 2 t 8t <15
Pasteur/CI 13 146 t 3 132 t 7 167 t 5 155 t 6 63 t 13 >752096
￿
VIRUSES AS THERAPEUTIC AGENTS
u o ::
.o0 8 a mb a
c
3 p ., 4
y
.n u
uU
4 ~~ U
row C . tl:
a ~Uro
. u O C
Ow~-
"L h
a
N
Sy 0- v v W .0 ,
'~ a 3 0
8a°U
' £r' X
￿
-6 O
Abz h N
z aCV4
0 oq~ .o
o ~ a
o >O
,» o O~~
~~U w
a .?
a
y 4
U
4y zr
L H ~ ~ U
N q C CV CL U 1
wa ~aOLDSTONE ET AL .
￿
2097
FIGURE 3.
￿
Comparisons of amino acid divergence among proteins encoded by the SRNA of
theLCMVARM Clone 13 andLCMV Pasteur. TheSRNAencodestwo proteins, theGP from
its 5' end, and the NP from the 3' end. The GPs ofARM Clone 13 and Pasteur contain 499
amino acids, and the NPs contain 558 .
GP and Clone 13 GP For the NP, the difference was 22 of 558 amino acids that
characterized theprotein of both viruses . Divergence occurred atrandom throughout
both molecules. No specific type of mutation was noted such as theC to U transi-
tions recently reported with another negative strand virus that causes persistent in-
FIGURE 4 . LCMV Pasteur
(PAST) andLCMV Clone (Cl)
13 replicate preferentially in
CD4* lymphocytes. The upper
panel illustrates an infectious
center assay on CD4* and
CD4ni1 lymphocytes recovered
from 7-mo-old NODmice per-
sistently infected with PAST.
From left to right, 105 , 104 , and
10 3 PBL were incubated with a
confluent monolayer of Vero
cells . Plaques were read 5 d
later. The lower panel records
the purity of the lymphocyte
populations used in the infec-
tious center assay. Cells were
obtained from the "-- portion
of the display.
P n 31- 41- 4L ZL 145 1U l2Z 154 1551 111 1IZ ZL1
Clone 13 GLY ILE LYS VAL THR ILE SER ARG CYS ASK ARG GLN
Pasteur SER VAL ASK ILE SER LEU PRO GLY ARM - ALA SER
252 253 254 2111 313 334 334 342 34fl 324 344 434 411
Clone 13 LEU SER PHE VAL ALA SER GLU LEU PRO LYS ASK LEU ASK
Pasteur PHE ALA LEU THR GLU THR GLN ILE ALA ARG LYS ILE SER
NP as no. 21r .- V_ 65_ 54_ 44_ 114 124 143 1a 154 244
Clone 13 SER ASK ARG LYS SER PRO GLN ILE LYS SER TYR
Pasteur THR SER ILE GLU THR LEU LYS NET ARG ASK -
2711 2&3 312 334 395? 34Z 4ll 424 4Z4 4B1 544
Clone 13 VAL ARG GLY PRO ALA ALA VAL ALA LYS ARG LYS
Pasteur ALA LYS ALA SER VAL VAL THR THR ARG LYS ARG2098
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fection (18, 19). Hence, the S RNA is clearly linked to prevention of IDDM, but
we are, at present, unable to identify the region more precisely.
LCMV Pasteurand LCMV ARM Clone 53B both prevent IDDM (Table 1). Be-
cause ofsequence variability between LCMV Pasteur andARM Clone 13 variant,
it was possible to easily detect reassortants between these two viruses. In contrast,
LCMV ARM and Clone 13 show high sequence conservation with complete ho-
mology in the NPandjust two base substitutionsin theGP (16; Salvato et al., manu-
script submitted for publication). Reassortants between these two strains have, so
far, not been generated. However, sequencing shows two mutations in the GP, one
leading to a significant amino acid substitution. Such data (16; Salvatoet al., manu-
script submitted forpublication), inconjunctionwith results reported here, suggest
that the structural determinant capable of blocking IDDM likely maps to the GP
of LCMV. However, the precise mapping of the IDDM-preventing trait of these
viruses awaits the ability to make recombinants of the S RNA or the acquisition
ofinfectious cDNA. None ofthese have yet been accomplished. The recent ability
to make cDNA from another negative strand virus, influenza (20), suggests that a
similar approach may be applied to LCMV. With this technology, the precise gene
and its component needed to prevent IDDM can be mapped.
Viruses caninfect, and haveprofoundeffectson, cellsthat participate in immune
responses, with resultant immunosuppression or immune enhancement (reviewed
in references 21 and 22). Several studies have focused on manipulating immune re-
sponses of autoimmunedisorders, and a variety ofthese diseases have been success-
fullycontrolled. Examples are use ofLCMV to abrogate IDDMinboth NODmice
(1)and BB diabetes-prone rats (23), aswell asleukemia/lymphomaofMRL/lprmice
(M. B. A. Oldstone and R. Ahmed, unpublished data); lactic dehydrogenase virus
to inhibit experimental allergic encephalomyelitis (24) and measles virus to prevent
nephrotic nephrosis (25). Bacterial and fungal products have long been manipu-
latedtoprovidetherapeutic agents. Itshould bepossibleto similarly harness viruses
or their products towards that goal.
Summary
Nonobese diabetic (NOD) mice are the experimental prototype oftype 1 insulin-
dependent diabetes mellitus (IDDM). These mice develop a characteristic autoim-
mune lesion in the pancreatic islets of Langerhans, where infiltrating lymphocytes
destroy/3 cells, resultingin hypoinsulinemia, hyperglycemia, ketoacidosis, anddeath.
This IDDM, whichclosely resemblesthat inhumans, ispreventedbyinfectingNOD
mice withparticular strainsoflymphocytic choriomeningitis virus (LCMV), including
Armstrong 53b, Traub, WE, and Pasteur. In contrast, the LCMV Armstrong 53b
variant, Clone 13, failsto abort IDDM. Hence, althoughClone 13 establishes aper-
sistent infection that endures throughout the life spans ofNOD mice, their hyper-
glycemia, hypoinsulinemia, and lymphocytic infiltration into the islets of Langer-
hans still occur. Geneticreassortantviruses generatedbetween theIDDMtherapeutic
strain ofLCMV Pasteur and the nontherapeutic variant, LCMV Clone 13, were
used to treat NOD mice. By using such reassortants and both parental strains of
virus to infect NOD mice, the prevention ofIDDM wasmapped to the S RNA seg-
ment of LCMV Pasteur.We thank Sandra Shyp and Antoinette Tishon for excellent technical assistance.
Receivedforpublication 4January 1990.
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